POSITIVE ESSENTIAL3 STUDY RESULTS ARE HERE!
We are excited to share that we recently announced positive results from our Essential3 program for patients treated with ulixacaltamide. This is the first positive Phase 3 program for a drug in development for essential tremor (ET). The results highlight the potential of ulixacaltamide to be the first treatment designed for people with ET and mark an important advancement for the ET community.
We are especially grateful to everyone who has participated in the Essential3 program and to all the ET advocates, community members and families whose voices inform our daily work. We recognize the urgent need for more and better treatment options, and we remain committed to making this a reality.
Praxis is committed to bringing this much-needed medication to the ET community. We will continue to keep the community informed as we engage with the Food and Drug Administration (FDA) on the next steps for the submission of the ulixacaltamide new drug application (NDA), which is the formal application that a company uses to ask the FDA to approve a new medicine.
